Peak Pharmaceuticals, Inc.
PKPH
Other OTC1.55
USD
- -
- -
Peak Pharmaceuticals, Inc.
PKPH
(Other OTC)
Recent
price
1.55
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Peak Pharmaceuticals, Inc. (PKPH) operates as Retrieve Medical Holdings, Inc. following its March 2023 reverse triangular merger with Retrieve Medical, Inc., through which it develops and commercializes proprietary healthcare software utilizing data mining, clinical decision support, natural language processing, and algorithmic testing to analyze patients' medical records, lab results, physician notes, radiology reports, and EKG interpretations in real-time; the patented Retrieve Dx platform generates diagnostic guidance for chronic conditions, simplifies documentation, reduces coding overhead, and integrates with major electronic health record systems including Epic, Cerner/Oracle, and cloud-based environments via SMART on FHIR standards, targeting emergency departments in U.S. medical centers. Retrieve Medical, Inc. and Peak BioPharma Corp. serve as wholly-owned subsidiaries. The company, originally incorporated in Nevada in 2007 as Surf A Movie Solutions Inc. with multiple name changes culminating in Peak Pharmaceuticals in 2014, maintains headquarters at 376 Main Street, Suite 100, Bedminster, New Jersey 07921, and leases approximately 1,500 square feet of office space there expiring in June 2026. Recent developments include a 1-for-200 reverse stock split effective February 2023 prior to the merger; ongoing share issuances for cash under subscription agreements, consultancy services, loan incentives, penalties, and interest through September 2025, increasing outstanding common shares from 22.1 million at September 30, 2024, to 25.7 million by September 30, 2025; a Regulation CF offering in 2024; and receipt of approximately $1.2 million in funding announced in October 2024, supporting software expansion amid technical defaults on various convertible and promissory notes totaling over $450,000 in principal.
Company News
Financial Review: Peak Pharmaceuticals (OTCMKTS:PKPH) versus Cyclacel Pharmaceuticals (NASDAQ:BGMS)